APA (7th ed.) Citation

Dash, R. P., Tichý, T., Veeravalli, V., Lam, J., Alt, J., Wu, Y., . . . Rais, R. (2019). Enhanced Oral Bioavailability of 2‑(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs. Molecular pharmaceutics, 16(10), 4292-4301. https://doi.org/10.1021/acs.molpharmaceut.9b00637

Chicago Style (17th ed.) Citation

Dash, Ranjeet P., et al. "Enhanced Oral Bioavailability of 2‑(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from Its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs." Molecular Pharmaceutics 16, no. 10 (2019): 4292-4301. https://doi.org/10.1021/acs.molpharmaceut.9b00637.

MLA (9th ed.) Citation

Dash, Ranjeet P., et al. "Enhanced Oral Bioavailability of 2‑(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from Its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs." Molecular Pharmaceutics, vol. 16, no. 10, 2019, pp. 4292-4301, https://doi.org/10.1021/acs.molpharmaceut.9b00637.